The Middle East and North Africa (MENA) pharmaceutical market, long characterised by its fragmentation and diverse regulatory requirements, is undergoing a significant transformation. Driven by the dual pressures of the COVID-19 pandemic and ambitious national visions for economic diversification and healthcare sovereignty, health authorities across the region are spearheading reforms aimed at harmonisation, acceleration, and enhanced patient safety. For global pharmaceutical companies and local stakeholders, staying abreast of these changes is no longer optional - it is critical for market access and success.
This article explores the most recent and impactful updates shaping the regulatory framework of this dynamic region.
The GCC Drive Towards Harmonisation: A Unified Front
The most powerful trend continues to be the collaborative effort by the Gulf Cooperation Council (GCC) countries - Saudi Arabia, the United Arab Emirates, Bahrain, Kuwait, Oman, and Qatar - through the GCC Centralised Registration Procedure.
Recent Enhancements include:
- Reliance Pathways: Several GCC member states are now formally adopting reliance mechanisms on approvals from reference agencies like the FDA, EMA, MHRA, TGA and Health Canada. This significantly shortens the review timeline for innovative drugs that have already undergone rigorous assessment in these jurisdictions. The UAE's Drug Establishment (EDE) and Saudi Arabia's Food and Drug Authority (SFDA) have been at the forefront of implementing these pathways.
- Streamlined Technical Requirements: There is a continuous effort to harmonise the technical dossier requirements (CTD format), stability study conditions for the region's climate, and the need for local clinical data, which is increasingly being waived for certain drug classes if robust global data is available.
- Joint Inspection Initiatives: The GCC is moving towards mutual recognition of Good Manufacturing Practice (GMP) inspections, reducing the need for duplicate audits by each national authority and accelerating the supply chain process.
Saudi Arabia’s SFDA: A Beacon of Innovation and Acceleration
The Saudi Food and Drug Authority (SFDA) has firmly established itself as a regional leader and a model for regulatory modernisation.
- Digital Transformation: The SFDA has fully embraced digitalisation through its “E-SDR” platform. This end-to-end electronic system manages product registrations, renewals, and variations, enhancing transparency and reducing processing times. The platform is continuously updated with new e-services, making interactions with the authority more efficient.
- Accelerated Pathways for Innovation: The SFDA has robust and actively used pathways for priority reviews. These are designed for breakthrough therapies, orphan drugs, and treatments addressing unmet medical needs. By requiring strong evidence of superiority over existing options, the SFDA is ensuring that Saudi patients gain faster access to the most advanced medical treatments.
- Focus on Local Clinical Trials: As part of Saudi Vision 2030, there is a strong push to develop the kingdom as a clinical research hub. The SFDA has streamlined the process for Clinical Trial Application (CTA) approvals and is actively encouraging both local and international sponsors to conduct studies within the country, which in turn generates region-specific data to support future registrations.
The UAE: Consolidating its Status as a Life Sciences Hub
The UAE continues to refine its regulatory processes to solidify its position as a gateway to the wider MENA region.
- MOHAP’s System: Like Saudi Arabia, the UAE’s MOHAP has its advanced digital portal, for all pharmaceutical regulatory activities. This has been instrumental in reducing paperwork and providing applicants with real-time status updates.
- A market is now open for advanced therapies: Most agents there are asking for advanced therapies and are less attracted towards traditional generics.
- Valuation-Based Pricing: The UAE is increasingly moving towards a value-based pricing model, considering the clinical and economic value of new medicines, a shift from traditional cost-plus pricing. This requires manufacturers to prepare robust health economic dossiers to justify their pricing proposals.
Egypt: Embracing Regulatory Agility and Local Manufacturing
Egypt, with its large population and expanding universal health insurance system, is a market of immense importance.
- Egyptian Drug Authority (EDA) Reforms: The EDA has been actively working to clear application backlogs and improve review cycle times. A key recent focus has been on encouraging local manufacturing and technology transfer.
- Incentives for Local Production: The government offers tangible incentives for locally manufactured products, including faster review times and preferential status in the national tender process. This policy is reshaping market strategies for multinational companies, many of whom are now seeking local partners.
- Biosimilars and Generics Focus: Given the pressure to provide cost-effective medicines to a large population, the EDA has established clear and evolving guidelines for the registration of biosimilars and complex generics, ensuring they meet stringent quality and efficacy standards.
Emerging Trends Reshaping the Entire Region
Beyond country-specific updates, several cross-cutting trends are evident:
- Advanced Therapy Medicinal Products (ATMPs): Regulators in Saudi Arabia, the UAE, and Qatar are developing specific frameworks for the approval of cell and gene therapies, recognising their unique nature and the need for specialised assessment and long-term follow-up.
- Enhanced Pharmacovigilance (PV): There is a universal tightening of pharmacovigilance requirements. Spontaneous reporting is no longer sufficient; authorities now expect detailed Risk Management Plans (RMPs), structured Periodic Safety Update Reports (PSURs), and the presence of a locally responsible Qualified Person for Pharmacovigilance (QPPV).
As a conclusion, the MENA regulatory landscape is shifting from a collection of isolated, slow-moving bureaucracies to a network of agile, patient-centric, and internationally aligned authorities. The direction is clear: towards greater harmonisation, digitalisation, and a focus on value and innovation.
For pharmaceutical companies, this evolving environment demands a proactive and strategic approach. Success will belong to those who invest in understanding these nuanced updates, build strong local partnerships, embrace digital submission platforms, and prepare robust, value-driven dossiers. The region's commitment to reform presents not just a challenge to navigate, but a tremendous opportunity to bring transformative medicines to a growing and increasingly accessible patient population.
Don’t miss out - see course dates for ‘Mastering CTD Submissions in the MENA Region’ and reserve your spot today: https://ipi.academy/product/details/2688/mastering-ctd-submissions-in-the-mena-region
Published on Oct 15, 2025 by